MMDA (drug)

MMDA

Clinical data
Routes of administration	Oral, Insufflation, Rectal
ATC code	none
Legal status
Legal status	AU: S9 (Prohibited) CA: Schedule I DE: Anlage I (Controlled) UK: Class A US: Schedule I
Identifiers
IUPAC name 1-(7-Methoxy-1,3-benzodioxol-5-yl)propan-2-amine
CAS Number	13674-05-0
PubChem CID	26175
ChemSpider	24386
UNII	RG7FY73ZAA
Chemical and physical data
Formula	C11H15NO3
Molar mass	209.24 g/mol
3D model (Jmol)	Interactive image
SMILES O1c2cc(cc(OC)c2OC1)CC(N)C

MMDA (3-methoxy-4,5-methylenedioxyamphetamine; 5-methoxy-MDA) is a psychedelic and entactogen drug of the amphetamine class. It is an analogue of lophophine, MDA, and MDMA.

MMDA was described by Alexander Shulgin in his book PiHKAL. Shulgin lists the dosage range of MMDA as 100–250 mg. The first symptoms appear within 30–60 minutes following . MMDA produces euphoria and loving warmth, and attenuates feelings such as anxiety and loneliness. MMDA also produces eyes-closed visuals, a state of drowsiness, muscle relaxation, and time dilation. Side effects include moderate mydriasis, dizziness, sensations of heat or cold, and trembling. The imagery is generally realistic, and often related to everyday perception of people, landscapes, or objects. The effects of MMDA usually reach a peak during the first hour following the initial symptoms, and begin to wane during the second hour, and usually completely disappear by the end of the fifth hour.

In his 1973 book, The Healing Journey, Claudio Naranjo explored the psychotherapeutic potential of MMDA. Like MDA, he found that MMDA facilitates communication and suggested it has potential applications in psychotherapy. Worldwide as of 2005^[update], MMDA has not been approved for any human applications.